Thymosin alpha 1 (Tα1) is a synthetic immune modulator with the strongest clinical support in severe acute pancreatitis, where trial data link it to fewer extrapancreatic infections and better CD4+ T cell counts, along with promising but less conclusive evidence in viral hepatitis and cancer treatment support. Evidence quality varies sharply by condition, and dosing, timing, and patient selection all shape outcomes. Anyone considering Tα1 for a specific health condition should talk to a physician familiar with immunomodulatory therapy before starting.